Fundz

Lucid Diagnostics reported raising $22 Million in an initial SEC Form D filing, from an offering of $22 Million

PUBLIC · LUCDDec 06, 2024

Amount Raised

$22 Million

$22 Million sold, per SEC Form D (first sale Nov 22, 2024)

Round Type

Venture

New YorkBiotechnology

Quick answer

Lucid Diagnostics raised $22 Million in a funding round, dated November 22, 2024. Lucid Diagnostics is based in New York, New York, United States.

How much did Lucid Diagnostics raise?
Lucid Diagnostics raised $22 Million in a funding round on November 22, 2024.
What does Lucid Diagnostics do?
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).
Where is Lucid Diagnostics based and how big is it?
Lucid Diagnostics is based in New York, New York, United States. Fundz records about 106 employees.
Who are the decision-makers at Lucid Diagnostics?
Fundz holds 5 contacts at Lucid Diagnostics, including the Senior Vice President of Sales. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Lucid Diagnostics that raised within 45 days of this round, from Fundz verified event records.

  • Agrobiomics raised $1.5M (Seed) on January 6, 2025.
  • Orbis Medicines raised $93M (Series A) on January 6, 2025.
  • Outset Medical raised $3.9M (Seed) on January 3, 2025.
  • General Proximity raised $16M (Seed) on January 3, 2025.
  • Botanic Healthcare raised $30M (Pre-Seed) on January 3, 2025.
  • Carna raised $3.4M (Seed) on January 3, 2025.

Who to call at Lucid Diagnostics, and when

A new round usually means Lucid Diagnostics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Lucid Diagnostics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Lucid Diagnostics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Lucid Diagnostics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Lucid Diagnostics

Location

360 MADISON AVENUE

New York, New York, United States

About

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Lucid Diagnostics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

5 contacts
Verified contactsJohn, Senior Vice President of Sales hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Lucid Diagnostics's next move

See what Strategic adds

Lucid Diagnostics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.